Ignite Creation Date:
2025-12-24 @ 12:20 PM
Ignite Modification Date:
2025-12-24 @ 12:20 PM
Study NCT ID:
NCT02571361
Status:
COMPLETED
Last Update Posted:
2018-02-12
First Post:
2015-10-07
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010149', 'term': 'Pain, Postoperative'}], 'ancestors': [{'id': 'D011183', 'term': 'Postoperative Complications'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D010146', 'term': 'Pain'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000082', 'term': 'Acetaminophen'}, {'id': 'D007052', 'term': 'Ibuprofen'}], 'ancestors': [{'id': 'D000083', 'term': 'Acetanilides'}, {'id': 'D000813', 'term': 'Anilides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000814', 'term': 'Aniline Compounds'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D010666', 'term': 'Phenylpropionates'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 556}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-11'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-02', 'completionDateStruct': {'date': '2018-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-02-09', 'studyFirstSubmitDate': '2015-10-07', 'studyFirstSubmitQcDate': '2015-10-07', 'lastUpdatePostDateStruct': {'date': '2018-02-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2015-10-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Nausea at 6 hours postoperatively (Verbal rating scale)', 'timeFrame': '6 hours postoperatively', 'description': 'Level of nausea at 6 hours postoperatively. Verbal rating scale: none, mild, moderate or severe'}, {'measure': 'Nausea at 24 hours postoperatively (Verbal rating scale)', 'timeFrame': '24 hours postoperatively', 'description': 'Level of nausea at 24 hours postoperatively. Verbal rating scale: none, mild, moderate or severe'}, {'measure': 'Vomiting the first 24 hours postoperatively', 'timeFrame': '0-24 hours postoperatively', 'description': 'Number of vomiting episodes (0-24 hours) measured in the periods 0-6 and 6-24 hours postoperatively'}, {'measure': 'Anti-emetic treatment the first 24 hours postoperatively', 'timeFrame': '0-24 hours postoperatively', 'description': 'Consumption of ondansetron in the period 0-24 hours postoperatively'}, {'measure': 'Sedation at 6 hours postoperatively (Verbal rating scale)', 'timeFrame': '6 hours postoperatively', 'description': 'Level of sedation at 6 hours postoperatively. Verbal rating scale: none, mild, moderate or severe'}, {'measure': 'Sedation at 24 hours postoperatively (Verbal rating scale)', 'timeFrame': '24 hours postoperatively', 'description': 'Level of sedation at 24 hours postoperatively. Verbal rating scale: none, mild, moderate or severe'}, {'measure': 'Blood loss intraoperatively', 'timeFrame': 'intraoperatively', 'description': 'Blood loss during the surgical procedure (intraoperatively)'}, {'measure': 'Days alive and outside hospital within 90 days after surgery.', 'timeFrame': '0-90 days postoperatively', 'description': 'Days alive and outside hospital within 90 days after surgery.'}, {'measure': 'Dizziness at 6 hours postoperatively (Verbal rating scale)', 'timeFrame': '6 hours postoperatively', 'description': 'Level of dizziness at 6 hours postoperatively. Verbal rating scale: none, mild, moderate or severe'}, {'measure': 'Dizziness at 24 hours postoperatively (Verbal rating scale)', 'timeFrame': '24 hours postoperatively', 'description': 'Level of dizziness at 24 hours postoperatively. Verbal rating scale: none, mild, moderate or severe'}], 'primaryOutcomes': [{'measure': 'Morphine consumption the first 24 hours postoperatively', 'timeFrame': '0-24 hours postoperatively', 'description': 'Total need for morphine administered as BOTH patient controlled analgesia (PCA) for the first 24 hours postoperatively AND supplemental morphine administered at the post-anaesthesia unit the first hour postoperatively. Bolus 2.0 mg; lockout: 10 min'}, {'measure': 'Serious adverse events', 'timeFrame': '0-90 days postoperatively', 'description': 'Serious adverse events, including death, within 90 days after surgery defined as SAE (according to ICH-GCP-guidelines) except "prolongation of hospitalisation"'}], 'secondaryOutcomes': [{'measure': 'Pain during movement at 6 hours postoperatively (visual analogue scale)', 'timeFrame': '6 hours postoperatively', 'description': 'Pain scores (visual analogue scale (VAS)) with active 30 degrees flexion of the hip at 6 hours postoperatively. No pain = 0; worst imaginable pain = 100'}, {'measure': 'Pain during movement at 24 hours postoperatively (visual analogue scale)', 'timeFrame': '24 hours postoperatively', 'description': 'Pain scores (visual analogue scale (VAS)) with active 30 degrees flexion of the hip at 24 hours postoperatively. No pain = 0; worst imaginable pain = 100'}, {'measure': 'Pain at rest at 6 hours postoperatively (visual analogue scale)', 'timeFrame': '6 hours postoperatively', 'description': 'Pain scores (visual analogue scale (VAS)) at rest at 6 hours postoperatively. No pain = 0; worst imaginable pain = 100'}, {'measure': 'Pain at rest at 24 hours postoperatively (visual analogue scale)', 'timeFrame': '24 hours postoperatively', 'description': 'Pain scores (visual analogue scale (VAS)) at rest at 24 hours postoperatively. No pain = 0; worst imaginable pain = 100'}, {'measure': 'Adverse events', 'timeFrame': '0-24 hours postoperatively', 'description': 'Number of patients with one or more adverse events in the intervention period (0-24 hours)'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Acetaminophen', 'Ibuprofen', 'Arthroplasty, Replacement, Hip'], 'conditions': ['Pain, Postoperative']}, 'referencesModule': {'references': [{'pmid': '28069072', 'type': 'BACKGROUND', 'citation': 'Thybo KH, Hagi-Pedersen D, Wetterslev J, Dahl JB, Schroder HM, Bulow HH, Bjorck JG, Mathiesen O. PANSAID - PAracetamol and NSAID in combination: study protocol for a randomised trial. Trials. 2017 Jan 10;18(1):11. doi: 10.1186/s13063-016-1749-7.'}, {'pmid': '30747964', 'type': 'DERIVED', 'citation': 'Thybo KH, Hagi-Pedersen D, Dahl JB, Wetterslev J, Nersesjan M, Jakobsen JC, Pedersen NA, Overgaard S, Schroder HM, Schmidt H, Bjorck JG, Skovmand K, Frederiksen R, Buus-Nielsen M, Sorensen CV, Kruuse LS, Lindholm P, Mathiesen O. Effect of Combination of Paracetamol (Acetaminophen) and Ibuprofen vs Either Alone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty: The PANSAID Randomized Clinical Trial. JAMA. 2019 Feb 12;321(6):562-571. doi: 10.1001/jama.2018.22039.'}, {'pmid': '29017585', 'type': 'DERIVED', 'citation': 'Thybo KH, Jakobsen JC, Hagi-Pedersen D, Pedersen NA, Dahl JB, Schroder HM, Bulow HH, Bjorck JG, Overgaard S, Mathiesen O, Wetterslev J. PANSAID-PAracetamol and NSAID in combination: detailed statistical analysis plan for a randomised, blinded, parallel, four-group multicentre clinical trial. Trials. 2017 Oct 10;18(1):465. doi: 10.1186/s13063-017-2203-1.'}], 'seeAlsoLinks': [{'url': 'http://www.pansaid.dk', 'label': 'Trial Website'}]}, 'descriptionModule': {'briefSummary': 'Trial name: PAracetamol and NSAID in combination: A randomised, blinded, parallel, 4-group clinical trial\n\nTrial acronym: PANSAID\n\nBackground: Effective postoperative pain management is essential for the well-being and rehabilitation of the surgical patient. No "gold standard" exists after total hip arthroplasty (THA) and combinations of different non-opioid medications are used with virtually no evidence for additional analgesic efficacy compared to monotherapy.\n\nObjectives: The objective of this trial is to investigate the analgesic effects and safety of paracetamol and ibuprofen and their combination in different dosages after THA.\n\nIntervention: Patients are randomised to 4 groups: A) paracetamol 1 g x 4 and ibuprofen 400 mg x 4; B) paracetamol 1 g x 4 and placebo (ibuprofen); C) placebo (paracetamol) and ibuprofen 400 mg x 4; and D) paracetamol 0,5 g x 4 and ibuprofen 200 mg.\n\nDesign: Placebo controlled, parallel 4-group, multicentre trial with adequate centralised computer-generated allocation sequence and allocation concealment with varying block size and stratification by site. Blinding of assessor, investigator, caregivers, patients, and statisticians.\n\nSample size: 556 eligible patients are needed to detect a difference of 10 mg morphine the first postoperative day with a standard deviation of 20 mg and a type 1 error rate of 0,004 (two-sided) and a type 2 error rate of 0,10.', 'detailedDescription': 'Trial name: PAracetamol and NSAID in combination: A randomised, blinded, parallel, 4-group clinical trial\n\nTrial acronym: PANSAID\n\nBackground: Effective postoperative pain management is essential for the well-being and rehabilitation of the surgical patient. No "gold standard" exists after total hip arthroplasty (THA) and combinations of different non-opioid medications are used with virtually no evidence for additional analgesic efficacy compared to monotherapy.\n\nObjectives: The objective of this trial is to investigate the analgesic effects and safety of paracetamol and ibuprofen and their combination in different dosages after THA.\n\nIntervention: Patients are randomised to 4 groups: A) paracetamol 1 g x 4 and ibuprofen 400 mg x 4; B) paracetamol 1 g x 4 and placebo (ibuprofen); C) placebo (paracetamol) and ibuprofen 400 mg x 4; and D) paracetamol 0,5 g x 4 and ibuprofen 200 mg.\n\nDesign: Placebo controlled, parallel 4-group, multicentre trial with adequate centralised computer-generated allocation sequence and allocation concealment with varying block size and stratification by site. Blinding of assessor, investigator, caregivers, patients, and statisticians.\n\nSample size: 556 eligible patients are needed to detect a difference of 10 mg morphine the first postoperative day with a standard deviation of 20 mg and a type 1 error rate of 0,004 (two-sided) and a type 2 error rate of 0,10.\n\nSub-studies: We preplan the following sub-studies. :\n\n1. A subgroup analysis of benefit outcomes (pain and opioid consumption) with respect to the following sub-groups: sex, age (below vs above 65 years old), ASA-score (I+II vs III), Use of analgesic medication before surgery (none vs any) and anaesthetic technique (general anaesthesia vs. spinal anaesthesia). Please find a detailed protocol at www.pansaid.dk\n2. A subgroup analysis of harm (serious adverse events and adverse events) with respect to the following groups sex, age (below vs above 65 years old), use of NSAIDs before surgery, and ASA-score (I+II vs III). Please find a detailed protocol at www.pansaid.dk\n3. Longer follow-up than the specified 90 days (1 year)\n4. An analysis of the association between VAS-scores and opioid consumption\n5. Time-to-event analyses regarding use of PCA-morphine\n6. An analysis of the association between preoperative analgesic use and pain/morphine consumption\n7. An analysis of the individual patients: how many will achieve "no worse than mild pain" (NRS\\<3). Please find a detailed protocol at www.pansaid.dk\n\nMore sub-studies may be performed post-hoc and they will be clearly identified as such.\n\nOversight of amendments and approvals Protocol version 2: Approved 12 August 2015: First approved version of the trial protocol\n\nProtocol version 3: Approved 21 January 2016: Clarification of what happens in case of an SAE and definition of major protocol violations\n\nProtocol version 4: Approved 15 June 2016: Clarification of the primary outcome, clarification that steroids are not permitted in the intervention period, and addition of an exploratory outcome (dizziness)\n\nProtocol version 5: Approved 21 December 2016: Clarification of the exclusion criteria of contraindication to paracetamol and addition of stub-studies'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Scheduled for unilateral, primary Total Hip Arthroplasty (THA)\n* Age \\> 18\n* ASA 1-3.\n* BMI \\> 18 and \\< 40\n* Women in the fertile age must have negative urine HCG pregnancy test\n* Patients who gave their written informed consent to participating in the trial after having fully understood the contents of the protocol and restrictions.\n\nExclusion Criteria:\n\n* Patients who cannot cooperate with the trial.\n* Concomitant participation in another trial\n* Patients who cannot understand or speak Danish.\n* Daily use of strong opioids (tramadol and codein are accepted)\n* Patients with allergy to the medicines used in the trial.\n* Contraindications against NSAID, for example previous ulcer, heart failure, liver failure, or renal failure (eGRF \\< 60 ml/kg/1,73m2), known thrombocytopenia (\\<100 mia/L)\n* Patients suffering from alcohol and/or drug abuse - based on the investigator's judgement."}, 'identificationModule': {'nctId': 'NCT02571361', 'acronym': 'PANSAID', 'briefTitle': 'PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial', 'organization': {'class': 'OTHER', 'fullName': 'Naestved Hospital'}, 'officialTitle': 'PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial', 'orgStudyIdInfo': {'id': 'SM2-KHT-2015 - v2'}, 'secondaryIdInfos': [{'id': '2015-002239-16', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Treatment A:', 'description': 'Paracetamol 1g + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.', 'interventionNames': ['Drug: Paracetamol (1g x 4)', 'Drug: Ibuprofen (400 mg x 4)']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Treatment B:', 'description': 'Paracetamol 1g + placebo orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.', 'interventionNames': ['Drug: Paracetamol (1g x 4)', 'Drug: Placebo (x4)']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Treatment C:', 'description': 'Placebo + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.', 'interventionNames': ['Drug: Ibuprofen (400 mg x 4)', 'Drug: Placebo (x4)']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Treatment D:', 'description': 'Paracetamol 0,5 g + ibuprofen 200 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.', 'interventionNames': ['Drug: Paracetamol (0,5 g x 4)', 'Drug: Ibuprofen (200 mg x 4)']}], 'interventions': [{'name': 'Paracetamol (1g x 4)', 'type': 'DRUG', 'otherNames': ['Acetaminophen'], 'description': 'Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively', 'armGroupLabels': ['Treatment A:', 'Treatment B:']}, {'name': 'Ibuprofen (400 mg x 4)', 'type': 'DRUG', 'description': 'Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively', 'armGroupLabels': ['Treatment A:', 'Treatment C:']}, {'name': 'Paracetamol (0,5 g x 4)', 'type': 'DRUG', 'otherNames': ['Acetaminophen'], 'description': 'Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively', 'armGroupLabels': ['Treatment D:']}, {'name': 'Ibuprofen (200 mg x 4)', 'type': 'DRUG', 'description': 'Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively', 'armGroupLabels': ['Treatment D:']}, {'name': 'Placebo (x4)', 'type': 'DRUG', 'description': 'Given in 6 hour intervals the first 24 hours postoperatively', 'armGroupLabels': ['Treatment B:', 'Treatment C:']}]}, 'contactsLocationsModule': {'locations': [{'zip': '2605', 'city': 'Copenhagen', 'state': 'Brøndby', 'country': 'Denmark', 'facility': 'Gildhøj Privathospital', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'zip': '4300', 'city': 'Holbæk', 'country': 'Denmark', 'facility': 'Holbæk Hospital', 'geoPoint': {'lat': 55.7175, 'lon': 11.71279}}, {'zip': '4600', 'city': 'Køge', 'country': 'Denmark', 'facility': 'Køge Hospital', 'geoPoint': {'lat': 55.45802, 'lon': 12.18214}}, {'zip': '4800', 'city': 'Nykøbing Falster', 'country': 'Denmark', 'facility': 'Nykøbing Falster Hospital', 'geoPoint': {'lat': 54.76906, 'lon': 11.87425}}, {'zip': '4700', 'city': 'Næstved', 'country': 'Denmark', 'facility': 'Næstved Hospital', 'geoPoint': {'lat': 55.22992, 'lon': 11.76092}}, {'zip': '5000', 'city': 'Odense', 'country': 'Denmark', 'facility': 'Odense University Hospital (OUH)', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}], 'overallOfficials': [{'name': 'Daniel Hägi-Pedersen, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Department of Anaesthesiology, Næstved Hospital'}, {'name': 'Kasper H Thybo, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Department of Anaesthesiology, Næstved Hospital'}, {'name': 'Ole Mathiesen, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Department of Anaesthesiology, Køge Hospital'}, {'name': 'Jørgen B Dahl, MD, DMSc', 'role': 'STUDY_CHAIR', 'affiliation': 'Department of Anaesthesiology, Bispebjerg Hospital'}, {'name': 'Jørn Wetterslev, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Copenhagen Trial Unit, Center for Clinical Intervention Research'}, {'name': 'Martin Pohlman, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Department of Anaesthesiology, Nykøbing Falster Hospital'}, {'name': 'Hans Henrik Bülow, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Department of Anaesthesiology, Holbæk Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Daniel Hägi-Pedersen', 'class': 'OTHER'}, 'collaborators': [{'name': 'Copenhagen Trial Unit, Center for Clinical Intervention Research', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Consultant', 'investigatorFullName': 'Daniel Hägi-Pedersen', 'investigatorAffiliation': 'Naestved Hospital'}}}}